EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

TET2 as a Context‐Dependent Epigenetic Integrator in Clonal Hematopoiesis, Inflammation, Cancer, and Immunotherapy

XiaoJie Liu, Jiangchen Liu, Liu Feng, Dan Xu, Xianling Wei, Dekuai Tong iD

Cell Biochemistry and Function · 2026

DOI: 10.1002/cbf.70287 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cell Biochemistry and Function, 2026. Verfasst von XiaoJie Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Affiliated Hospital of Jiaxing University, The First Hospital of Jiaxing, Jiaxing City, China. Hauptthemen laut MEDLINE: Immunotherapy, Inflammation, DNA-Binding Proteins, Proto-Oncogene Proteins. Die Arbeit nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Zhejiang Provincial Medical and Health Science and Technology Program, Science and Technology Program of Jiaxing City, Jiaxing Supporting Discipline Medical Imaging Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ten‐Eleven Translocation 2 (TET2) is an Fe(II)‐ and α‐ketoglutarate‐dependent dioxygenase that initiates active DNA demethylation by oxidizing 5‐methylcytosine (5mC). Beyond this enzymatic role, TET2 links DNA methylation dynamics with chromatin regulation, cellular metabolism, immune‐cell identity, and treatment response in a context‐dependent manner. Loss‐of‐function mutations in TET2 are among the most frequent genetic events in age‐related clonal hematopoiesis of indeterminate potential (CHIP), where they are associated with higher risks of hematological malignancies and cardiovascular disease. Human genetic and clinical studies support these associations, while experimental models suggest that mutant hematopoietic clones can promote myeloid inflammatory programs through enhancer remodeling, NLRP3 inflammasome activation, IL‐1β/IL‐6 signaling, and altered inflammatory resolution. In solid tumors and cancer therapy, TET2 has more variable effects: tumor‐cell‐intrinsic TET2 loss can contribute to immune escape or therapeutic resistance in selected settings, whereas TET2 disruption in engineered T cells can enhance memory‐like persistence and anti‐tumor activity, with possible long‐term oncogenic risk. This narrative, mechanism‐oriented review integrates current evidence on TET2 biology across clonal hematopoiesis, inflammation, cancer, and immunotherapy. We focus on evidence level, cell type, direction of TET2 alteration, and metabolic or therapeutic context as determinants of divergent TET2 functions. TET2 has traditionally been described as a DNA demethylation enzyme, but recent studies increasingly place it among context‐dependent regulators of immune and disease phenotypes. The unresolved issue is why TET2 loss, inhibition, activation, or engineered deletion can produce distinct, and sometimes opposing, effects in hematopoietic stem/progenitor cells, macrophages, tumor cells, neurons, microglia, and CAR‐T cells. This review uses four variables—cell type, direction of alteration, functional layer, and microenvironmental or therapeutic context—to interpret evidence from CHIP, hematologic malignancies, cardiovascular inflammation, solid tumors, and immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyInflammationDNA-Binding ProteinsProto-Oncogene ProteinsNeoplasmsClonal HematopoiesisEpigenesis, GeneticHumansDioxygenasesAnimalsHematopoiesis

Stichwörter der Autor:innen

DNA demethylationTET2cancer immunotherapyclonal hematopoiesiscontext dependenceinflammationmetabolism

Substanzen

DioxygenasesTET2 protein, humanDNA-Binding ProteinsProto-Oncogene Proteins

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Affiliated Hospital of Jiaxing University, The First Hospital of Jiaxing, Jiaxing City, China.
  • Department of Biomedical Science, Faculty of Life Sciences and Medicine, King's College London, London, UK.
  • Department of Blood Transfusion, Affiliated Hospital of Jiaxing University, The First Hospital of Jiaxing, Jiaxing City, China.
  • Department of Radiology, Affiliated Hospital of Jiaxing University, The First Hospital of Jiaxing, Jiaxing City, China.

ORCID-Profile: Dekuai Tong

Förderung

  • Zhejiang Provincial Medical and Health Science and Technology Program
  • Science and Technology Program of Jiaxing City
  • Jiaxing Supporting Discipline Medical Imaging Project
  • Demonstration Program for the Reform and High-Quality Development of Public Hospitals

Zitieren

APA

Liu, X., Liu, J., Feng, L., Xu, D., Wei, X., & Tong, D. (2026). TET2 as a Context‐Dependent Epigenetic Integrator in Clonal Hematopoiesis, Inflammation, Cancer, and Immunotherapy. Cell Biochemistry and Function. https://doi.org/10.1002/cbf.70287

Vancouver

Liu X, Liu J, Feng L, Xu D, Wei X, Tong D. TET2 as a Context‐Dependent Epigenetic Integrator in Clonal Hematopoiesis, Inflammation, Cancer, and Immunotherapy. Cell Biochemistry and Function. 2026. doi:10.1002/cbf.70287

BibTeX
@article{Liu2026,
  author = {Liu, XiaoJie and Liu, Jiangchen and Feng, Liu and Xu, Dan and Wei, Xianling and Tong, Dekuai},
  title = {TET2 as a Context‐Dependent Epigenetic Integrator in Clonal Hematopoiesis, Inflammation, Cancer, and Immunotherapy},
  journal = {Cell Biochemistry and Function},
  year = {2026},
  doi = {10.1002/cbf.70287}
}
Kostenlos starten →